GPE – Page 15 – Talk Bio

Pfizer’s European Manufacturing Vulnerable to Potential US Tariffs, CEO Warns

7 months ago talkbio0Tagged Albert, Bourla, chain disruption, Drug Industry, European (ethnic group), Manufacturing, Pfizer, Tension, TNFRSF19 gene, U.S.

Pfizer, Albert Bourla, European manufacturing, US tariffs, pharmaceutical industry, trade tensions, supply chain disruption

Massive Layoffs Sweep Federal Health Agencies: Thousands of Workers Impacted Across HHS

7 months ago talkbio0Tagged Administration occupational activities, Centers for Disease Control and Prevention (U.S.), federal, Health agencies, HHS layoffs, Myasthenic Syndromes, Congenital, NIH, NIH Mouse, probationary workers, Transplant Registry Unified Management Program, United States Food and Drug Administration

HHS layoffs, federal health agencies, probationary workers, Trump administration, workforce reduction, CDC, NIH, FDA, CMS

Septerna Halts Phase 1 Trial of SEP-786 Due to Unexpected Bilirubin Elevations

7 months ago talkbio0Tagged Agonist, Bilirubin, Clinical Trials, Discontinuation (procedure), Hypoparathyroidism, PTH1R gene, SEP-786, Septerna

Septerna, SEP-786, clinical trial discontinuation, hypoparathyroidism, bilirubin elevation, PTH1R agonist, biotech setback

Robert F. Kennedy Jr. Confirmed as HHS Secretary in Close Senate Vote

7 months ago talkbio0Tagged Administration occupational activities, CHARGE Syndrome, Confirmation, Health Policy, Healthy, RFK Jr., Secretary, Senate, Skepticism, Transplant Registry Unified Management Program, Vaccines

RFK Jr., HHS Secretary, Senate confirmation, Trump administration, vaccine skepticism, healthcare policy, Make America Healthy Again

FDA Approves Pfizer’s Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

7 months ago talkbio0Tagged Adcetris, Antibody-Drug Conjugates, Approved, BRENTUXIMAB, Combined Modality Therapy, Diffuse Large B-Cell Lymphoma, LBCL, Pfizer, United States Food and Drug Administration, vedotin

Adcetris, brentuximab vedotin, FDA approval, large B-cell lymphoma, LBCL, DLBCL, antibody-drug conjugate, Pfizer, combination therapy

Axplora Invests €50M in GLP-1 Manufacturing Expansion at Mourenx, France

7 months ago talkbio0Tagged alpha 1-antitrypsin, Axplora, biology (field), CDMO, Chromatography, Diabetes, expansion, France, Glucagon-Like Peptide 1, Manufacturing, Mourenx, Obesity, production

Axplora, GLP-1, manufacturing expansion, Mourenx, France, CDMO, API production, chromatography, diabetes, obesity, biologic therapies

Federal Judge Orders Trump Administration to Comply with Ruling Against Federal Funding Freeze

7 months ago talkbio0Tagged Administration occupational activities, Biomechanical compliance, federal, Judge, Lawyer (occupation), Transplant Registry Unified Management Program, Trump, Violation

federal funding freeze, court order violation, Judge John McConnell, Trump administration, state attorneys general, federal grants, compliance

U.S. Hospitals Urge Trump to Exempt Medical Supplies and Pharmaceuticals from New Tariffs

7 months ago talkbio0Tagged Canada, chain disruption, China, Health care facility, medical supplies, Mexico, patient safety, tariffs

Tariffs, medical supplies, pharmaceuticals, American Hospital Association, China, Mexico, Canada, healthcare costs, supply chain disruption, patient safety

Pharmaceutical Giants Bristol Myers Squibb and Kyowa Kirin Announce 119 Layoffs in New Jersey Amid Restructuring Efforts

7 months ago talkbio0Tagged cost-cutting, Drug Industry, Kirin, Kyowa, Myers, New Jersey, restructuring, squibb

Bristol Myers Squibb, Kyowa Kirin, layoffs, New Jersey, restructuring, pharmaceutical industry, cost-cutting, workforce reduction

Bristol Myers Squibb and Kyowa Kirin Announce New Rounds of Layoffs in New Jersey

7 months ago talkbio0Tagged cost-cutting measures, Jersey pharma, Kirin, Kyowa, Myers, Pharmaceutical Layoffs, squibb

Pharmaceutical layoffs, workforce reduction, cost-cutting measures, Bristol Myers Squibb, Kyowa Kirin, New Jersey pharma industry